Renovacor Announces Upcoming Presentation at Keystone Symposia’s Heart Failure: Mechanisms and Therapies Conference
September 26 2022 - 4:25PM
Business Wire
Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on
delivering innovative precision therapies to improve the lives of
patients and families battling genetically-driven cardiovascular
and mechanistically-related diseases, today announced that
preclinical studies characterizing the progression of cardiac
dysfunction and mortality in a BAG3 haploinsufficiency mouse model
of dilated cardiomyopathy will be featured in an upcoming poster
presentation at Keystone Symposia’s Heart Failure: Mechanisms and
Therapies Conference. The conference is taking place from September
28 – October 1, 2022, at the Beaver Run Resort in Breckenridge,
CO.
The poster (#2001), titled, “Progression of cardiac dysfunction
and mortality in a Bcl2-associated athanogene-3 (BAG3)
haploinsufficiency mouse model of dilated cardiomyopathy (DCM),”
will be presented from 7:30 – 10:00 p.m. MST on September 30, 2022,
during Poster Session 2. The poster’s presenting author is Valerie
Myers, Ph.D., Senior Director of Preclinical Science at
Renovacor.
About Renovacor
Renovacor is a biotechnology company focused on delivering
innovative precision therapies to improve the lives of patients and
families battling genetically-driven cardiovascular and
mechanistically-related diseases. The company’s lead program in
BAG3-associated dilated cardiomyopathy (DCM) uses gene transfer
technology to address the monogenic cause of this severe form of
heart failure. Renovacor’s vision is to bring life-changing
therapies to patients living with serious genetic cardiovascular
and related diseases, by developing medicines that target the
underlying cause of disease and provide a transformative benefit
and significant improvement to quality of life.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of the “safe harbor” provisions of the United
States Private Securities Litigation Reform Act of 1995, as
amended. These forward-looking statements generally are identified
by the words “believe,” “project,” “expect,” “anticipate,”
“estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,”
“may,” “should,” “will,” “would,” “will be,” “will continue,” “will
likely result,” and similar expressions. These forward-looking
statements are based upon current estimates and assumptions of the
Company and its management and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release. Factors
that may cause actual results to differ materially from current
expectations include, but are not limited to: competition, the
ability of the company to grow and manage growth, maintain
relationships with customers and suppliers and retain its
management and key employees; the Company's ability to successfully
advance its current and future product candidates through
development activities, preclinical studies and clinical trials and
costs related thereto; the Company’s ability to submit an IND
related to REN-001 on its anticipated timeline, and any challenges
related to the clearance of such IND by the FDA; the timing, scope
and likelihood of regulatory filings and approvals, including final
regulatory approval of our product candidates; changes in
applicable laws or regulations; the possibility that the Company
may be adversely affected by other economic, business or
competitive factors, including inflationary pressures; the
Company’s estimates of expenses and profitability; the evolution of
the markets in which the Company competes; the ability of the
Company to implement its strategic initiatives and continue to
innovate its existing products; the ability of the Company to
defend its intellectual property; the impact of the COVID-19
pandemic on the Company’s business, supply chain and labor force;
and the risks and uncertainties described in the “Risk Factors”
section of the Company's annual and quarterly and reports filed the
Securities Exchange Commission. These filings identify and address
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Renovacor assumes
no obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Renovacor gives no assurance that it
will achieve its expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220926005810/en/
Brooks Rahmer Renovacor, Inc. 610-424-2627 ir@renovacor.com
Renovacor (AMEX:RCOR)
Historical Stock Chart
From Oct 2024 to Nov 2024
Renovacor (AMEX:RCOR)
Historical Stock Chart
From Nov 2023 to Nov 2024